The findings challenge long-standing assumptions about therapy-related cancers. They also highlight how drug actions can substitute for genetic changes in tumor development. An international team of ...

The scientific community rarely witnesses paradigm shifts that redefine entire fields of medicine. Marc Malone’s years of ...

Primary liver cancer is the third leading cause of cancer-related deaths, of which hepatocellular carcinoma (HCC) accounts ...

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line ...

Ginseng has long been used in traditional medicine to replenish Qi and address deficiency syndromes, often manifesting as ...

An international research team bringing together Prof. Kirsten Kübler from the Berlin Institute of Health at Charité (BIH), and colleagues from Broad Institute of MIT and Harvard, Mass General Brigham ...

Primary liver cancer is the third leading cause of cancer-related deaths, of which hepatocellular carcinoma (HCC) accounts ...

Kazia Therapeutics ( ($KZIA) ) just unveiled an announcement. On September 11, 2025, Kazia Therapeutics announced significant findings from a ...

The latest update is out from Celcuity ( (CELC) ).

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...